CHOICELY
The Eurovision Song Contest (ESC), the world’s largest live music event, has renewed their mobile app in time for this year’s event in Malmö, Sweden. The app was built using Choicely’s no code app platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501446902/en/
Eurovision Song Contest built their new mobile app with a no code platform. The app was built using Choicely’s no code app platform. The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media. (Graphic: Business Wire)
“We were looking for a specialized partner who enables us to develop our app with speed and flexibility, so we can better serve the Eurovision fans across the globe,“ says Dave Goodman, ESC Digital and Communications Manager for Contest organizers, the European Broadcasting Union.
“We definitely got all of that in Choicely, and more,” Goodman emphasizes.
With Choicely, the app can be built without coding, using a visual drag and drop interface instead – like Wix or Wordpress for mobile apps.
“Despite Choicely being a no code platform, we got a fully tailormade app that matches our needs and our brand. Making improvements is quick and easy. We can focus on engaging our fans!” adds Dave Goodman from the EBU.
The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media.
During the Semi-Finals and Grand Final, viewers around the world can also easily vote through the app.
“We are proud to co-operate with the Eurovision Song Contest!” says Kaius Meskanen, CEO of Choicely. “It’s a legendary contest with a passionate global fanbase, and it reflects in everything they do,” Meskanen says.
“Together we have created a pixel-perfect app to serve the Eurovision fans, during the shows and in between them. It’s great to see the ESC organization enjoying the benefits of no code, like lower development costs, agile updates, and a better overall experience for the fans,” Meskanen points out.
Choicely was founded in Finland and it’s used by leaders in media, sports and entertainment companies, and across a range of industries in over 50 countries.
The renewed Eurovision Song Contest app can be found in Apple App Store and Google Play Store.
The Eurovision Song Contest is the world’s largest live music event. It is organized annually by the European Broadcasting Union (EBU), the world’s foremost alliance of public service media (PSM).
The competition, in which participating public service broadcasters that are Members of the EBU, send a new song to represent their nation, has taken place every year since 1956 except in 2020.
27 broadcasters have won the competition at least once.
37 broadcasters will take part in the 2024 Eurovision Song Contest in Malmö, Sweden hosted by SVT.
The 2023 competition reached over 170 million viewers around the world on TV and online.
The EBU represents 112 media organisations in 56 countries in Europe, the Middle East, and Africa; and have an additional 31 Associates in Asia, Africa, Australia, and the Americas. The EBU strives to secure a sustainable future for public service media.
Choicely’s no code app builder offers a simple, fast and affordable way to build and maintain high quality mobile apps. Choicely is based in Finland and Switzerland and currently serves businesses in over 50 countries. Choicely’s customers include the Eurovision Song Contest, Miss Universe, ITV Studios / Love Island TV Shows, and Iceland's national broadcasting organization RÚV.
Learn more about Choicely on their website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501446902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom